Fair-Value Report — CANbridge Pharmaceuticals (1228.HK)

Insider Signal

Verified Snapshot

Currency note: company reports in RMB. HKD/RMB exchange rate used: 1 RMB = 1.065 HKD (mid-2026 estimate). All financial figures verified from stockanalysis.com, minichart.com.sg, and Benzinga; cross-checked against HKEX AGM notice (June 2, 2026). Net cash estimate: Dec-2025 net cash (RMB 66.6M − RMB 15.0M debt = RMB 51.6M = HKD 54.9M) plus WuXi's HKD 200M injection (March 10, 2026) less estimated 6-month operating outflows (HKD 30M at HKD 5M/month, 41 employees post-restructuring).

Business Description

CANbridge Pharmaceuticals is a HK-listed rare disease biopharmaceutical company focused on Greater China. It has three NMPA-approved enzyme-replacement therapies:

• Hunterase® (idursulfase-IT) — MPS II (Hunter syndrome); approved; commercialization transferred to Baheal as exclusive CSO
• Livmarli® (maralixibat) — PFIC (progressive familial intrahepatic cholestasis); NMPA-approved; commercialization via Baheal CSO
• Gaurunning® (imiglucerase) — Gaucher disease (type 1); NMPA marketing clearance May 2025, first prescription July 2025. China's first domestically-developed ERT for Gaucher at approximately half the price of imported alternatives (~RMB 1M/patient/year). Entered China's innovative drug supplemental insurance list December 2025.

Business model transition (FY2025): CANbridge appointed Baheal subsidiaries as exclusive CSO for all three products across mainland China, Hong Kong, and Macau. Under this arrangement, Baheal does the selling; CANbridge earns product supply revenue at wholesale prices plus milestone/royalty payments. The company received a one-time RMB 50M engagement fee from Baheal (August 2025) and was paid HKD ~100M for an equity stake. As of early 2026, the company has 41 employees (drastically reduced from prior years) and has shut its US operations (triggering a one-off lease termination gain in FY2025).

Valuation

Methodology Selection

CANbridge is a pre-commercial / early-commercial biopharma undergoing a business model transition. DCF is inappropriate (revenue too small, unstable, and transitioning). The correct methodology is: EV/Revenue (sector multiple) + net-cash floor + scenario analysis on Gaurunning commercial ramp. A P/B approach is secondary (book value not confirmed; no recent NAV). No DCF.

WACC reference (indicative, for context): HK 10Y government bond ~3.8%; biopharma beta ~1.5–2.0; implied WACC ~12–16%. Not used in primary valuation.

Revenue Scenario Analysis

Key driver: Gaurunning's penetration of China's Gaucher disease market. Estimated addressable patient population: 6,000–8,000 patients (low prevalence, severe underdiagnosis). At RMB 1M/patient/year, the total addressable market is RMB 6–8B annually. At 1%, 3%, and 8% penetration respectively (bear/base/bull):

Revenue scenarios: Bull assumes Gaurunning captures ~3% of 8,000-patient addressable market (240 patients × RMB 700K net-to-CANbridge supply price) = RMB ~168M Gaurunning + stable RMB 30-50M Hunterase/Livmarli = RMB ~200M. Base assumes ~120 patients treated by end of 2027 + existing products. Bear assumes model transition disrupts revenues further and Gaurunning ramp is slow. EV/Revenue multiples benchmarked to global rare-disease peers (BioMarin 5–7×, Ultragenyx 8–12×, RemeGen HK ~8–12×); applied conservatively given CANbridge's small scale and revenue quality risk. Net cash estimate of HKD 225M is as of approximately July 2026 (see methodology note above). Shares: 595.44M (verified).

Reverse Read

At HKD 1.940 per share and net cash of ~HKD 225M, the market is assigning an enterprise value of ~HKD 930M to the operating business. At a 7× revenue multiple (peer median for early-commercial rare disease), this implies the market is pricing in revenue of HKD 133M (RMB 125M) — approximately 2.4× FY2025's reported HKD 55.6M.

Achieving RMB 125M revenue requires Gaurunning to reach approximately 50–60 treated patients on a recurring basis (at HKD ~2M/patient supply price) plus stable contributions from Hunterase and Livmarli. Given the December 2025 insurance listing, this is plausible within 18–24 months — but is not guaranteed, and it is already in the price. At HKD 2.5991 (Baheal's purchase price), the market was pricing in RMB 200M+ of revenue — a much more optimistic scenario that would require Gaurunning to become a commercial success within 12 months.

Peer Comparison

Peer data is approximate and sourced from public market data. Comparison is illustrative; CANbridge is significantly smaller and in an earlier, more uncertain stage than most listed peers. BioMarin and Ultragenyx have fully-built commercial organizations; CANbridge has delegated commercialization to Baheal. CANbridge trades at a premium to peer median EV/Revenue (16.7× vs. 7–10×), which is NOT justified given declining revenue and non-recurring earnings. This premium reflects speculative enthusiasm around Gaurunning and is the primary valuation risk.

Conclusion

Verdict: HOLD. The Baheal open-market purchase (June 30, 2026) is a genuine secondary-market transaction, not a subscription. However, the signal quality is limited: Baheal is a connected party and commercial partner protecting its distribution position after WuXi diluted their stake. They paid HKD 2.5991 — 30% above the current price of HKD 1.940 — and are currently sitting on a 25% paper loss on this specific purchase, undermining the forward conviction signal.

At HKD 1.940, CANbridge trades at approximately 17× trailing EV/Revenue on a declining top-line. The reported FY2025 net profit of RMB 14.8M is non-recurring (driven by the Baheal engagement fee and a US lease termination gain). The underlying business remains operationally loss-making.

The genuine upside case rests on Gaurunning — China's first domestically-developed enzyme replacement therapy for Gaucher disease at half the price of imports, now with supplemental insurance coverage (December 2025). If patient ramp is robust (50+ patients within 12 months, 200+ within 3 years), revenue could reach RMB 150–200M and the stock could re-rate toward HKD 3.00–3.60.

However, the base case (50% weight) values the company at HKD 1.63, fractionally below the current price, implying HOLD. The probability-weighted fair value is HKD 1.84 — approximately in line with current trading. Given (1) the valuation premium to peers, (2) the declining revenue, and (3) the weak signal quality (connected party, post-dilution top-up), we do not see sufficient asymmetry to recommend a buy at these levels.

Key catalyst to watch: Gaurunning patient identification and monthly prescription volumes from Baheal's CSO network. A sustained ramp to 50+ treated patients by end of 2026 would justify upgrading to Speculative Buy.

Key Risks

• Revenue model dependency: 100% of commercial revenue funneled through one CSO partner (Baheal). If the Baheal relationship sours or Baheal fails commercially, CANbridge has no direct sales force.
• Recurring profitability: FY2025 profit is non-recurring. FY2026 may revert to losses without the Baheal engagement fee and US lease gain.
• Cash runway: Estimated HKD 225M net cash (post-WuXi injection); at HKD 5–10M/month burn (41 employees + operations), runway is 22–45 months. A revenue shortfall could require another equity raise, diluting further.
• Gaurunning ramp risk: Ultra-rare disease markets are hard to penetrate. Patient identification is slow; insurance coverage does not guarantee reimbursement volumes. Management guided optimistically on Gaucher at a market with historically very few diagnosed patients in China.
• WuXi Biologics service dependency: WuXi is a 16.21% shareholder and the company's biologics manufacturing partner (connected-party framework agreement, June 2026). Any deterioration in WuXi's situation (US legislative risk, etc.) could affect CANbridge's supply chain.
• Small-cap data limits: No analyst coverage found; no broker price targets; limited trading liquidity. Data paucity may cause mispricing in either direction.
• Share dilution risk: Board has share issuance mandate. RSU and option grants approved at 2026 AGM (including a sizeable grant to CEO Dr. James Xue). Fully-diluted share count may be higher than the 595.44M reported.

Sources

• HKEX AGM Notice, CANbridge Pharmaceuticals (filed 2026-06-02) — shareholding disclosure, Baheal holding 97.15M shares = 16.26%
• CANbridge Pharmaceuticals Press Release — Baheal Strategic Partnership & Investment (August 13, 2025): canbridgepharma.com
• TipRanks/Marketscreener — WuXi Biologics HKD 200M subscription (March 2026), CANbridge Connected Service Deals (June 2026)
• Stockanalysis.com — HKG:1228 current price HKD 1.940, shares 595.44M, TTM revenue HKD 55.62M, net income HKD 16.49M (as of 2026-07-07)
• minichart.com.sg — FY2025 annual report highlights: net profit RMB 14.8M, cash RMB 66.6M, debt RMB 15M, 41 employees, Gaurunning insurance coverage Dec 2025
• Benzinga — Baheal deal analysis, Gaurunning pricing (~RMB 1M/patient/year), P/S context (August 2025)
• Yicai Global — Baheal USD 12.7M deal details and strategic context
• Alpha Spread / Alphaspread.com — FY2024 revenue RMB 85.1M, −17% YoY, 3Y CAGR 40%